Ticker Hub
ETON — AI Analysis & Sentiment
3 recent AI-generated analyses for ETON. Sentiment and confidence insights updated continuously.
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)
Eton Pharmaceuticals' new commercialization agreement for IMPAVIDO® enhances its rare disease portfolio with a proven, FDA-approved treatment. This...
May 19, 2026Eton Pharmaceuticals Reports First Quarter 2026 Financial Results
Eton Pharmaceuticals delivered strong Q1 results, turning profitable and significantly raising full-year revenue guidance. The company's expanding ...
May 14, 2026Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA™ (desmopressin acetate) Oral Solution
Eton Pharmaceuticals' FDA approval for DESMODA™ creates a significant new revenue stream, making it a compelling bullish opportunity. The stock's n...
Feb 25, 2026